



## **Spectrum Pharmaceuticals Announces Date for Third Quarter 2009 Corporate Update and Pipeline Review Conference Call**

IRVINE, Calif., Nov 06, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced the date and time for its third quarter 2009 corporate update and pipeline review conference call.

### **Conference Call**

**Friday, November 13, 2009 @ 1:00 p.m. Eastern/10:00 a.m. Pacific**

Domestic: 888-339-3507

International: 719-325-2342

Webcast and replays: [www.sppirx.com](http://www.sppirx.com)

Audio replays will be available through November 23, 2009

Domestic: 888-203-1112, passcode 4574342

International: 719-457-0820, passcode 4574342

### **About Spectrum Pharmaceuticals**

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. For more information, please visit the Company's website at [www.sppirx.com](http://www.sppirx.com).

*Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.*

*SPECTRUM PHARMACEUTICALS, INC. (TM), TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.*

© 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

SOURCE: Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Paul Arndt

Senior Manager, Investor Relations

949-788-6700 x216

Copyright Business Wire 2009